Obermatt
See Similar Stocks →

Spero Therapeutics

NSQ:SPRO · US84833T1034
BiotechnologySmall

360

77
Medium confidence — indicative
Profit price—
Owner Earnings Yield95
Dividend Yield1
Price/Sales100
EV / Gross Profit61
Price/Book67
Return on Capital97
Return on Equity91
EBIT Margin92
Gross Profitability92

Cash truth not applicable for financial companies.

Sales growth30
Profit growth96
Reinvestment16
Price momentum25
Debt load50
Debt serviceability51
Liquidity79
Analyst ratings1
Opinion Changes50
Price Target Upside6
Market mood25
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Spero Therapeutics generates returns well above its cost of capital, the foundation of durable shareholder value.

Based on 3/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2013
Employees37
Websitesperotherapeutics.com
ISINUS84833T1034
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
UrologyPulmonologyInfectious DiseasesBiotechnologyMedical DeviceTherapeutics

Description

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (‘MDR’) bacterial infections with high unmet need. The company…

Analysis

Quality compounder

Spero Therapeutics, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is uncertain. The company scores 20/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
100
—
—
—
Price/Earnings
—
—
—
—
Price/Book
67
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
81
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Spero Therapeutics with its peers
Regeneron Pharmaceuticals
NSQ:REGN
83
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Aclaris Therapeutics
NSQ:ACRS
28
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Tenax Therapeutics
NAQ:TENX
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Bright Minds Biosciences
CNX:DRUG
88
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Atea Pharmaceuticals
NSQ:AVIR
5
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Connect Biopharma Holdings
NMQ:CNTB
55
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →